Cargando…

Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries

Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Nick H., Fisher, Micah, Poch, David, Zhao, Carol, Shah, Mehul, Bartolome, Sonja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691927/ https://www.ncbi.nlm.nih.gov/pubmed/33282180 http://dx.doi.org/10.1177/2045894020935291

Ejemplares similares

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
por: White, R. James, et al.
Publicado: (2020)

Iranian Pulmonary Arterial Hypertension Registry
por: Masjedi, Mohammad Reza, et al.
Publicado: (2015)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Advanced pulmonary arterial hypertension: mechanical support and lung transplantation
por: Bartolome, Sonja, et al.
Publicado: (2017)

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
por: DuBrock, Hilary M., et al.
Publicado: (2021)

Erratum: Obesity in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Publicado: (2021)

Erratum: Obesity in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Publicado: (2022)

Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)
por: Minhas, Jasleen, et al.
Publicado: (2021)

Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry
por: Jansa, Pavel, et al.
Publicado: (2014)

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
por: Sodimu, Adetoun, et al.
Publicado: (2020)

Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension
por: Chung, Wook-Jin, et al.
Publicado: (2015)

Pulmonary arterial hypertension registries: past, present and into the future
por: Weatherald, Jason, et al.
Publicado: (2019)

Outcomes of cardiopulmonary resuscitation in patients with pulmonary arterial hypertension
por: Yang, Jenny Z., et al.
Publicado: (2022)

Corrigendum for health‐related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: And analysis from the Pulmonary Hypertension Association Registry
por: Minhas, J., et al.
Publicado: (2022)

Letter to the Editor regarding “Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?”
por: Fernandes, Timothy M., et al.
Publicado: (2020)

Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension
por: Wu, Sheryl, et al.
Publicado: (2022)

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
por: Hoeper, Marius M, et al.
Publicado: (2022)

Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations
por: Swinnen, Katleen, et al.
Publicado: (2019)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial
por: Gomberg-Maitland, Mardi, et al.
Publicado: (2019)

Pulmonary artery dissection in long standing idiopathic pulmonary arterial hypertension: A case report
por: Regalado, Luis, et al.
Publicado: (2021)

Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL)
por: Kopeć, Grzegorz, et al.
Publicado: (2020)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
por: Poch, David S.
Publicado: (2016)

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
por: Preston, Ioana R., et al.
Publicado: (2015)

Survival in pulmonary arterial hypertension: A brief review of registry data
por: Pauwaa, Sunil, et al.
Publicado: (2011)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
por: Hoeper, Marius M., et al.
Publicado: (2022)

Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature
por: Sanges, Sébastien, et al.
Publicado: (2016)

Erratum: Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Publicado: (2022)

Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension
por: Malhotra, Rajeev, et al.
Publicado: (2013)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

Predicting mortality during long-term follow-up in pulmonary arterial hypertension
por: Kylhammar, David, et al.
Publicado: (2021)

New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
por: Hinkamp, Colin A., et al.
Publicado: (2021)

Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry
por: Burger, Charles D., et al.
Publicado: (2014)

Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
por: Morrell, Nicholas W., et al.
Publicado: (2013)

Erratum: Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_10u6lllevhijo3hsr2c06skcr9